BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.

Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...

Last year, Moderna ( NASDAQ: MRNA) made headlines with its individualized mRNA cancer vaccine mRNA-4157 (V940), developed ...

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...

Pfizer has agreed to reimburse BioNTech for $364.5 million of the claimed royalties paid to NIH and $170.0 million of the claimed royalties paid to the University of Pennsylvania. Write to Dean Seal ...

Mike Tyson boxing event. Related Articles Netflix sets NFL streaming record with Christmas day games BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties HomeStreet Bank to ...